Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab

Figures & data

Table I.  Demographics of patients.

	No of patients (%)
Total no of patients	87
Age at diagnosis
< 50	45 (52)
≥ 50	42 (48)
Histology
Invasive ductal	80 (92)
Invasive lobular	2 (2)
Others	5 (6)
ER status
+ ve	41 (47)
− ve	46 (53)
PgR status *
+ ve	7 (8)
− ve	47 (54)
missing	33 (38)
Nodal status
+ ve	54 (62)
− ve	13 (15)
Not evaluable	20 (23)
Neoadj/ adjuvant treatment
Chemotherapy
None	18 (21)
Anthracycline-based	48 (55)
Non-anthracycline based	19 (22)
Unknown	2 (2)
Endocrine
None	50 (57)
Yes	37 (43)
Received Trastuzumab as
1^st line	43 (49)
2^nd line	24 (28)
3^rd line (+)	20 (23)

* PgR is normally only done in ER −ve patients.

Figure 1.  Kaplan-Meier survival of patients without CNS metastases.

Table II.  Prognostic factors for CNS metastases.

	Total No	CNS mets	Relative Risk of CNS metastases	95% CI	Significance
Patients		87	23
Age
< 50	45	7	1.0
≥ 50	42	16	1.1	0.5: 2.8	p = 0.8
ER status
+ ve	41	11	1.0
− ve	46	12	1.0	0.5: 2.4	p = 0.9
Nodal status
+ ve	54	15	1.0
− ve	13	3	1.1	0.3: 3.7	p = 0.9
Adj/Neoadj chemotherapy
None	18	6	1.0
Anthracycline	48	12	0.6	0.2: 1.5
Others	21	5	0.7	0.2: 2.3	p = 0.5
Adj/Neoadj endocrine
None	37	11	1.0
Yes	50	12	0.6	0.3: 1.3	p = 0.2
Received Trastuzumab as
1^st line	43	12	1.0
2^nd line	24	7	1.3	0.5: 3.2
3^rd line (+)	20	4	1.1	0.4: 3.4	p = 0.8
Site(s) of disease before Trastuzumab ^*
Soft tissue	58	14	0.7	0.3: 1.7	p = 0.5
Bone	40	11	1.0	0.5: 2.3	p = 1.0
Visceral	62	18	2.3	0.8: 6.2	p = 0.09
Trastuzumab
Single agent	41	10	1.0
With chemotherapy	46	13	1.0	0.4: 2.2	p = 0.9

* RR refers to relative risk compared to a patient without disease in this site.

Figure 2.  Kaplan Meier survival of patient from the start of trastuzumab treatment.